AltA-ZuZ Therapeutics

Novel small molecule for the Treatment of Inflammatory and Autoimmune Diseases

Leukocyte transendothelial migration is one of the most important steps in launching an inflammatory immune response and chronic inflammation can lead to devastating diseases. We developed a novel, potent, non-toxic and patentable inhibitor of transendothelial migration of immune cells. In vivo, compound GT73 exhibited significant therapeutic effects in inflammatory bowel disease (IBD)/Crohn’s disease, multiple sclerosis, Non-alcoholic fatty liver disease, and rheumatoid arthritis models. A detailed 28-day GLP toxicity profile of the lead compound in vivo did not reveal any toxic effects. GT73 provides a unique starting point for designing a novel class of leukocyte transmigration blocking agents with broad therapeutic applications in inflammatory and auto-immune pathologies.

Stage

Seed

Markets

BioPharma, BioTech

Seeking

$1M